Skip to content
Tallac Therapeutics, Inc
Tallac Therapeutics, Inc

News

Home
News
Latest News

Latest News

In Latest NewsPosted January 19, 2023

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer

More
In Latest NewsPosted November 11, 2022

Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting

More
In Latest NewsPosted July 28, 2022

Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors

More
In Latest NewsPosted May 19, 2022

Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors

More
In Latest NewsPosted April 15, 2021

Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer

More
In Latest NewsPosted March 4, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

More
In Latest NewsPosted December 1, 2020

Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

More

Categories

  • Latest News (7)
  • Publication and Data (4)

Recent Posts

  • Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
  • Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
  • Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
  • Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
  • Tallac SITC 2021 Presentation

Archives

  • January 2023
  • November 2022
  • July 2022
  • May 2022
  • October 2021
  • April 2021
  • March 2021
  • December 2020
  • November 2020
Tallac Therapeutics, Inc
  • (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Linkedin-in Envelope

Copyright © 2020-2023 Tallac Therapeutics, Inc. All Rights Reserved.